Redeye comments on Physitrack ahead of its Q3 results, due on 21 October (rescheduled from 31 October). We expect continued profitability improvements in Q3 2025e, driven by price increases in Lifecare, while softness in Wellness persists. Cost-efficient measures are supporting margins, and free cash flow generation remains intact; we anticipate debt reduction in the near term.
LÄS MER
